{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:43:37Z","timestamp":1792302217355,"version":"4.4.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007594","name":"Univerzita Komensk\u00e9ho v Bratislave","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015352","name":"Comenius University in Bratislava Faculty of Pharmacy","doi-asserted-by":"publisher","award":["GVRFaFUK\/1\/2023"],"award-info":[{"award-number":["GVRFaFUK\/1\/2023"]}],"id":[{"id":"10.13039\/100015352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejps.2025.107416","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:06:17Z","timestamp":1765818377000},"page":"107416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["1,3,5-Triazine-benzenesulfonamide hybrids: are they cytotoxic?"],"prefix":"10.1016","volume":"217","author":[{"given":"M\u00e1ria Bodn\u00e1r","family":"Mikulov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Hricov\u00edniov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Hanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6974-1363","authenticated-orcid":false,"given":"Gabriela","family":"Greifov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ejps.2025.107416_bib0001","doi-asserted-by":"crossref","first-page":"14247","DOI":"10.1021\/acsomega.3c01273","article-title":"Novel sulfonamide-triazine hybrid derivatives: docking, synthesis, and biological evaluation as anticancer agents","volume":"8","author":"Alelaimat","year":"2023","journal-title":"ACS. Omega"},{"key":"10.1016\/j.ejps.2025.107416_bib0002","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3389\/fonc.2020.01462","article-title":"CA IX stabilizes intracellular pH to maintain metabolic reprogramming and proliferation in hypoxia","volume":"10","author":"Benej","year":"2020","journal-title":"Front. Oncol"},{"issue":"20","key":"10.1016\/j.ejps.2025.107416_bib0003","article-title":"Synthesis and inhibition activity study of triazinyl-substituted amino(alkyl)-benzenesulfonamide conjugates with polar and hydrophobic amino acids as inhibitors of Human carbonic anhydrases I, II, IV, IX, and XII","volume":"22","author":"Bodn\u00e1r Mikulov\u00e1","year":"2021","journal-title":"Int. J. Mol. Sci"},{"issue":"2","key":"10.1016\/j.ejps.2025.107416_bib0004","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/ph14020167","article-title":"Advances in development of radiometal labeled amino acid-based compounds for cancer imaging and diagnostics","volume":"14","author":"Bodn\u00e1r Mikulov\u00e1","year":"2021","journal-title":"Pharmaceuticals. (Basel)"},{"issue":"14","key":"10.1016\/j.ejps.2025.107416_bib0005","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.3390\/molecules29143290","article-title":"Dual inhibitors of P-gp and carbonic anhydrase XII (hCA XII) against tumor multidrug resistance with piperazine scaffold","volume":"29","author":"Braconi","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2025.107416_bib0006","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejmech.2017.09.035","article-title":"1,3,5-Triazines: a promising scaffold for anticancer drugs development","volume":"142","author":"Cascioferro","year":"2017","journal-title":"Eur. J. Med. Chem"},{"issue":"29","key":"10.1016\/j.ejps.2025.107416_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202502122","article-title":"Sulfonamides: historical perspectives, therapeutic insights, applications, challenges, and synthetic strategies","volume":"10","author":"Chhablani","year":"2025","journal-title":"ChemistrySelect"},{"issue":"22","key":"10.1016\/j.ejps.2025.107416_bib0008","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1016\/j.bmc.2013.09.031","article-title":"Inhibition of human carbonic anhydrase isoforms I\u2013XIV with sulfonamides incorporating fluorine and 1,3,5-triazine moieties","volume":"21","author":"Ceruso","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejps.2025.107416_bib0010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1021\/acsmedchemlett.7b00478","article-title":"Synthesis and evaluation of a 18F-labeled triazinediamine analogue for imaging mutant IDH1 expression in gliomas by PET","volume":"9","author":"Chitneni","year":"2018","journal-title":"ACS. Med. Chem. Lett"},{"issue":"10","key":"10.1016\/j.ejps.2025.107416_bib0011","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.tibs.2007.09.001","article-title":"The PI3K inhibitor arsenal: choose your weapon!","volume":"32","author":"Crabbe","year":"2007","journal-title":"Trends. Biochem. Sci"},{"issue":"11","key":"10.1016\/j.ejps.2025.107416_bib0012","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.3390\/molecules28114278","article-title":"Antitumor activity of s-triazine derivatives: a systematic review","volume":"28","author":"Dai","year":"2023","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.ejps.2025.107416_bib0013","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann. Oncol"},{"issue":"16","key":"10.1016\/j.ejps.2025.107416_bib0014","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1016\/j.bmcl.2013.06.038","article-title":"Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity","volume":"23","author":"Dao","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"6","key":"10.1016\/j.ejps.2025.107416_bib0015","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jscs.2015.01.004","article-title":"Synthesis, characterization and antimicrobial activity of some new 4-(4-(2-isonicotinoylhydrazinyl)-6-((aryl)amino)-1,3,5-triazin-2-ylamino)-N-(pyrimidin-2-yl) benzenesulfonamides","volume":"20","author":"Desai","year":"2017","journal-title":"J. Saudi. Chem. Soc"},{"key":"10.1016\/j.ejps.2025.107416_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111718","article-title":"Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer","volume":"183","author":"Elmenier","year":"2019","journal-title":"Eur. J. Med. Chem"},{"issue":"1","key":"10.1016\/j.ejps.2025.107416_bib0017","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13065-024-01164-9","article-title":"Novel synthesis of new triazine sulfonamides with antitumor, antimicrobial and antiSARSCoV2 activities","volume":"18","author":"Ezzat","year":"2024","journal-title":"BMC. Chem"},{"issue":"2\u20133","key":"10.1016\/j.ejps.2025.107416_bib0018","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0163-7258(02)00179-1","article-title":"Protein kinases as targets for anticancer agents: from inhibitors to useful drugs","volume":"93","author":"Fabbro","year":"2002","journal-title":"Pharmacol. Ther"},{"issue":"12","key":"10.1016\/j.ejps.2025.107416_bib0019","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1016\/j.bmcl.2005.04.056","article-title":"Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX","volume":"15","author":"Garaj","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.ejps.2025.107416_bib0020","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.bmc.2019.02.050","article-title":"Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474","volume":"27","author":"Giddens","year":"2019","journal-title":"Bioorg. Med. Chem"},{"issue":"10","key":"10.1016\/j.ejps.2025.107416_bib0021","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2174\/187152010794728684","article-title":"Targeting focal adhesion kinase in neuroblastoma","volume":"10","author":"Gillory","year":"2010","journal-title":"Anticancer. Agents. Med. Chem"},{"issue":"2004","key":"10.1016\/j.ejps.2025.107416_bib0022","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/sj.leu.2403347","article-title":"Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074","volume":"18","author":"Grand","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2025.107416_bib0023","unstructured":"Greifov\u00e1, G., Hricov\u00edniov\u00e1, J., Hanko, M., Bodn\u00e1r Mikulov\u00e1, M., Miku\u0161, P., 2025. In Preparation."},{"key":"10.1016\/j.ejps.2025.107416_bib0024","series-title":"Progress in Heterocyclic Chemistry","author":"Gribble","year":"2019"},{"key":"10.1016\/j.ejps.2025.107416_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bioorg.2017.12.034","article-title":"Novel sulfonamide incorporating piperazine, aminoalcohol and 1,3,5-triazine structural motifs with carbonic anhydrase I, II and IX inhibitory action","volume":"77","author":"Havr\u00e1nkov\u00e1","year":"2018","journal-title":"Bioorg. Chem"},{"issue":"1","key":"10.1016\/j.ejps.2025.107416_bib0026","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bmcl.2013.11.023","article-title":"Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor","volume":"24","author":"Hortala","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejps.2025.107416_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.115997","article-title":"Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K\/mTOR","volume":"32","author":"Hu","year":"2021","journal-title":"Bioorg. Med. Chem"},{"issue":"1","key":"10.1016\/j.ejps.2025.107416_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-08-0801","article-title":"Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy","volume":"8","author":"Ihle","year":"2009","journal-title":"Mol. Cancer. Ther"},{"issue":"6","key":"10.1016\/j.ejps.2025.107416_bib0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood. Cancer. J"},{"issue":"9","key":"10.1016\/j.ejps.2025.107416_bib0031","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/syn.20919","article-title":"[76Br]BMK-152, a nonpeptide analogue, with high affinity and low nonspecific binding for the corticotropin-releasing factor type 1 receptor","volume":"65","author":"Jagoda","year":"2011","journal-title":"Synapse"},{"key":"10.1016\/j.ejps.2025.107416_bib0032","article-title":"Synthesis and antimicrobial evaluation of some novel trisubstituted s-triazine derivatives based on isatinimino, sulphonamido, and azacarbazole","volume":"2013","author":"Jain","year":"2012","journal-title":"J. Chem"},{"issue":"2","key":"10.1016\/j.ejps.2025.107416_bib0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","article-title":"Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma","volume":"11","author":"Konteatis","year":"2020","journal-title":"ACS. Med. Chem. Lett"},{"issue":"8","key":"10.1016\/j.ejps.2025.107416_bib0034","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.bmcl.2016.02.085","article-title":"Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors","volume":"26","author":"Kothayer","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.ejps.2025.107416_bib0035","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/14756366.2018.1481403","article-title":"Selective inhibition of carbonic anhydrase-IX by sulphonamide derivatives induces pH and reactive oxygen species-mediated apoptosis in cervical cancer HeLa cells","volume":"33","author":"Koyuncu","year":"2018","journal-title":"J. Enzyme. Inhib. Med. Chem"},{"issue":"1","key":"10.1016\/j.ejps.2025.107416_bib0036","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1080\/14756366.2020.1801674","article-title":"Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents","volume":"35","author":"Krasivin","year":"2020","journal-title":"J. Enzyme. Inhib. Med. Chem"},{"issue":"10","key":"10.1016\/j.ejps.2025.107416_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115453","article-title":"Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2","volume":"28","author":"Kuriwaki","year":"2020","journal-title":"Bioorg. Med. Chem"},{"issue":"4","key":"10.1016\/j.ejps.2025.107416_bib0039","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1021\/bc500034n","article-title":"Triazine-based tool box for developing peptidic PET imaging probes: syntheses, microfluidic radiolabeling, and structure\u2013Activity evaluation","volume":"25","author":"Li","year":"2014","journal-title":"Bioconjugate. Chem"},{"key":"10.1016\/j.ejps.2025.107416_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116680","article-title":"1,3,5-Triazine as a promising scaffold in the development of therapeutic agents against breast cancer","volume":"276","author":"Lim","year":"2024","journal-title":"Eur. J. Med. Chem"},{"key":"10.1016\/j.ejps.2025.107416_bib0041","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bioorg.2018.10.005","article-title":"Design, synthesis and biological evaluation of novel ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors","volume":"82","author":"Lolak","year":"2019","journal-title":"Bioorg. Chem"},{"issue":"1","key":"10.1016\/j.ejps.2025.107416_bib0042","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/14756366.2019.1707196","article-title":"Sulphonamides incorporating 1,3,5-triazine structural motifs show antioxidant, acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibitory profile","volume":"35","author":"Lolak","year":"2020","journal-title":"J. Enzyme. Inhib. Med. Chem"},{"key":"10.1016\/j.ejps.2025.107416_bib0043","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bioorg.2018.08.005","article-title":"Novel sulfonamides incorporating 1,3,5-triazine and amino acid structural motifs as inhibitors of the physiological carbonic anhydrase isozymes I, II and IV and tumor-associated isozyme IX","volume":"81","author":"Miku\u0161","year":"2018","journal-title":"Bioorg. Chem"},{"key":"10.1016\/j.ejps.2025.107416_bib0044","article-title":"Tumor associated carbonic anhydrase inhibitors: rational approaches, design strategies, structure activity relationship and mechanistic insights","volume":"10","author":"Nerella","year":"2024","journal-title":"Eur. J. Med. Chem. Rep"},{"key":"10.1016\/j.ejps.2025.107416_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130862","article-title":"Toward a treatment of antibacterial and antifungal infections: design, synthesis and in vitro activity of novel arylhydrazothiazolylsulfonamides analogues and their insight of DFT, docking and molecular dynamic simulations","volume":"1243","author":"Othman","year":"2021","journal-title":"J. Mol. Struct"},{"key":"10.1016\/j.ejps.2025.107416_bib0046","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12551-021-00795-9","article-title":"Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions","volume":"13","author":"Ovung","year":"2021","journal-title":"Biophys. Rev"},{"key":"10.1016\/j.ejps.2025.107416_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103239","article-title":"Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors","volume":"92","author":"Oudah","year":"2019","journal-title":"Bioorg. Chem"},{"issue":"7","key":"10.1016\/j.ejps.2025.107416_bib0048","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ddr.21704","article-title":"Hybrid molecules based on 1,3,5-triazine as potential therapeutics: a focused review","volume":"81","author":"Prasher","year":"2020","journal-title":"Drug. Dev. Res"},{"issue":"2","key":"10.1016\/j.ejps.2025.107416_bib0049","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3727\/096504017X14965111926391","article-title":"Inhibition of carbonic anhydrase IX by ureidosulfonamide inhibitor U104 reduces prostate cancer cell growth, but does not modulate daunorubicin or cisplatin cytotoxicity","volume":"26","author":"Riemann","year":"2018","journal-title":"Oncol. Res"},{"key":"10.1016\/j.ejps.2025.107416_bib0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri2036","article-title":"PI3K\u03b4 and PI3K\u03b3: partners in crime in inflammation in rheumatoid arthritis and beyond?","volume":"7","author":"Rommel","year":"2007","journal-title":"Nat. Rev. Immunol"},{"issue":"11","key":"10.1016\/j.ejps.2025.107416_bib0051","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2174\/0929867033457647","article-title":"Anticancer and antiviral sulfonamides","volume":"10","author":"Scozzafava","year":"2003","journal-title":"Curr. Med. Chem"},{"key":"10.1016\/j.ejps.2025.107416_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105313","article-title":"Design, synthesis, and evaluation of HIV-1 entry inhibitors based on broadly neutralizing antibody 447-52D and gp120 V3loop interactions","volume":"116","author":"Senapathi","year":"2021","journal-title":"Bioorg. Chem"},{"issue":"4","key":"10.1016\/j.ejps.2025.107416_bib0053","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3390\/molecules26040864","article-title":"s-triazine: a privileged structure for drug discovery and bioconjugation","volume":"26","author":"Sharma","year":"2021","journal-title":"Molecules"},{"issue":"17","key":"10.1016\/j.ejps.2025.107416_bib0054","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.1021\/acs.jmedchem.8b00922","article-title":"Tailoring the substitution pattern on 1,3,5-triazine for targeting cyclooxygenase-2: discovery and structure-activity relationship of triazine-4-aminophenylmorpholin- 3-one hybrids that reverse algesia and inflammation in swiss albino mice","volume":"61","author":"Singh","year":"2018","journal-title":"J. Med. Chem"},{"issue":"6","key":"10.1016\/j.ejps.2025.107416_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000363","article-title":"1,3,5-Triazine: a versatile pharmacophore with diverse biological activities","volume":"354","author":"Singh","year":"2021","journal-title":"Arch. Pharm"},{"key":"10.1016\/j.ejps.2025.107416_bib0056","series-title":"Cytotoxicity - A Crucial Toxicity Test For In Vitro Experiments","article-title":"Comparative analysis of cytotoxicity assays, from traditional to modern approaches","author":"Singhal","year":"2024"},{"issue":"8","key":"10.1016\/j.ejps.2025.107416_bib0057","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.bmc.2015.03.012","article-title":"Triazine-benzimidazole hybrids: anticancer activity, DNA interaction and dihydrofolate reductase inhibitors","volume":"23","author":"Singla","year":"2015","journal-title":"Bioorg. Med. Chem"},{"key":"10.1016\/j.ejps.2025.107416_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107483","article-title":"Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1 (R132H)\/IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: in vitro and in vivo preclinical investigations","volume":"149","author":"Tawfik","year":"2024","journal-title":"Bioorg. Chem"},{"key":"10.1016\/j.ejps.2025.107416_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108297","article-title":"Novel brain permeant mTORC1\/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex","volume":"180","author":"Theilmann","year":"2020","journal-title":"Neuropharmacol"},{"issue":"8","key":"10.1016\/j.ejps.2025.107416_bib0061","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.3390\/ijms21082924","article-title":"Synthesis, antitumor evaluation, molecular modeling and quantitative structure\u2013Activity relationship (QSAR) of novel 2-[(4-Amino-6-N-substituted-1,3,5-triazin-2-yl)methylthio]-4-chloro-5-methyl-N-(1H-benzo[d]imidazol-2(3H)-ylidene)benzenesulfonamides","volume":"21","author":"Tomorowicz","year":"2020","journal-title":"Int. J. Mol. Sci"},{"issue":"5","key":"10.1016\/j.ejps.2025.107416_bib0062","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-13-1897","article-title":"Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors","volume":"20","author":"Valentino","year":"2014","journal-title":"Clin. Cancer. Res"},{"issue":"12","key":"10.1016\/j.ejps.2025.107416_bib0063","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.ejhg.5200883","article-title":"Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders","volume":"10","author":"van Rhijn","year":"2002","journal-title":"Eur. J. Hum. Genet"},{"issue":"7","key":"10.1016\/j.ejps.2025.107416_bib0064","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.3390\/ijms22073685","article-title":"Synthesis, biological activity, and molecular dynamics study of novel series of a trimethoprim analogs as multi-targeted compounds: dihydrofolate reductase (DHFR) inhibitors and DNA-binding agents","volume":"22","author":"Wr\u00f3bel","year":"2021","journal-title":"Int. J. Mol. Sci"},{"issue":"5\u20136","key":"10.1016\/j.ejps.2025.107416_bib0066","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/00958972.2023.2208260","article-title":"A review on \u2018sulfonamides\u2019: their chemistry and pharmacological potentials for designing therapeutic drugs in medical science","volume":"76","author":"Zafar","year":"2023","journal-title":"J. Coord. Chem."},{"issue":"1","key":"10.1016\/j.ejps.2025.107416_bib0067","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21024-7","article-title":"Synthesis and anticancer activity of new benzensulfonamides incorporating striazines as cyclic linkers for inhibition of carbonic anhydrase IX","volume":"12","author":"Zain-Alabdeen","year":"2022","journal-title":"Sci. Rep"},{"issue":"37","key":"10.1016\/j.ejps.2025.107416_bib0068","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.2174\/0929867323666160814002150","article-title":"New molecular targets of anticancer therapy - current status and perspectives","volume":"23","author":"Zajac","year":"2016","journal-title":"Curr. Med. Chem"},{"issue":"2","key":"10.1016\/j.ejps.2025.107416_bib0069","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.urolonc.2021.10.003","article-title":"Targeted therapies: expanding the role of FGFR3 inhibition in urothelial carcinoma","volume":"40","author":"Zengin","year":"2022","journal-title":"Urol. Oncol"},{"key":"10.1016\/j.ejps.2025.107416_bib0070","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.ejmech.2017.11.005","volume":"143","author":"\u017bo\u0142nowska","year":"2018","journal-title":"Eur. J. Med. Chem"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725004130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725004130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:47:16Z","timestamp":1768934836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725004130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":65,"alternative-id":["S0928098725004130"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107416","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1,3,5-Triazine-benzenesulfonamide hybrids: are they cytotoxic?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107416"}}